Opus Genetics, Inc. Common Stock (IRD) is a publicly traded Healthcare sector company. As of October 21, 2026, IRD trades at $3.98 with a market cap of $317.81M and a P/E ratio of -5.76. IRD moved -0.87% today. Year to date, IRD is +89.15%; over the trailing twelve months it is +102.53%. Its 52-week range spans $0.65 to $7.07. Analyst consensus is strong buy with an average price target of $13.67. Rallies surfaces IRD's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
13 analysts cover IRD: 0 strong buy, 13 buy, 0 hold, 0 sell, and 0 strong sell. The consensus rating is strong buy. The average price target is $13.67.
| Metric | Value |
|---|---|
| Price | $3.98 |
| Market Cap | $317.81M |
| P/E Ratio | -5.76 |
| EPS | $-0.80 |
| Dividend Yield | 0.00% |
| 52-Week High | $7.07 |
| 52-Week Low | $0.65 |
| Volume | 25.27K |
| Avg Volume | 0 |
| Revenue (TTM) | $14.20M |
| Net Income | $-49.59M |
| Gross Margin | 0.00% |
13 analysts cover IRD: 0 strong buy, 13 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $13.67.